Name
Advances in Managing Metastatic Non-Small Cell Lung Cancer in the Era of Immune Checkpoint Inhibitors
Date & Time
Friday, October 23, 2020, 9:05 AM - 10:05 AM
Description
This activity is sponsored by PTCE and supported by educational grants from Merck Sharpe & Dohme Corp and Bristol Myers Squibb.
Speaker: Eve Segal PharmD, BCOP, University of Washington Medical Center/Seattle Cancer Care Alliance
Program Description
Lung cancer is one of the leading causes of cancer-related deaths worldwide. With the introduction of immunotherapies, significant advancements have been made in the treatment of patients diagnosed with metastatic non-small cell lung cancer. Through this activity, learners will gain an understanding of tumor genome testing in non-small cell lung cancer and will also become familiar with the place in therapy for immune checkpoint inhibitors. Tools to improve patient medication adherence and tactics to assist in the management of medication adverse events will be discussed throughout this presentation.
Lung cancer is one of the leading causes of cancer-related deaths worldwide. With the introduction of immunotherapies, significant advancements have been made in the treatment of patients diagnosed with metastatic non-small cell lung cancer. Through this activity, learners will gain an understanding of tumor genome testing in non-small cell lung cancer and will also become familiar with the place in therapy for immune checkpoint inhibitors. Tools to improve patient medication adherence and tactics to assist in the management of medication adverse events will be discussed throughout this presentation.
Target Audience: Oncology pharmacists, pharmacy technicians, physicians, and nurses
Type of Activity: Knowledge
Educational Objectives:
At the completion of this activity, pharmacists, physicians, and nurses will be able to:
At the completion of this activity, pharmacists, physicians, and nurses will be able to:
• Describe current therapy options in the treatment of metastatic non-small cell lung cancer (NSCLC), including emerging immune checkpoint inhibitors and the role of tumor genome testing
• Recognize adverse events associated with immune checkpoint inhibitor therapy and identify applicable prevention and management strategies
• Discuss effective tools the oncology care team can use to maximize therapeutic outcomes for patients with metastatic NSCLC
At the completion of this activity pharmacy technicians will be able to:
• Describe current therapy options in the treatment of metastatic non-small cell lung cancer (NSCLC)
• Recognize adverse events associated with immune checkpoint inhibitor therapy and recommendations for prevention and management
• Discuss effective tools that can be used to maximize therapeutic outcomes for patients with metastatic NSCLC
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (1.0 CEU) under the ACPE universal activity numbers 0290-0000-20-258-L05-P and 0290-0000-20-258-L05-T. The activity is available for CE credit on October 23, 2020.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education
(ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education™. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
(ACCME) through the joint providership of Physicians’ Education Resource®, LLC and Pharmacy Times Continuing Education™. Physicians’ Education Resource®, LLC is accredited by the ACCME to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC designates this live activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669 for 3 Contact Hours. Instructions for Completing the Activity and Receiving CPE Credit to receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation.
After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. Credit must be requested no later than December 23, 2020. CE credit will not be issued after this date.